Few weeks ago, our CEO Neringa Šeperienė was one of the few CEOs selected to participate in the InvestEU pitch coordinated by EuroQuity - Bpifrance that featured 5 high-potential startups led by women in the sectors of healthtech.
She did an interview with the EuroQuity-Bpifrance for their EuroQuityStories series in which I was able to share BrachyDOSE mission.
Take a look at QnA session.
Q: What drove you to create your company and what are your main goals?
A: The main driver which ignited us to create our own company was the knowledge that medical technologies in cancer treatment are reaching patients very slowly when they are made by big corporates. Our team decided that we could make a bigger impact and implement our solution to clinical use much faster if we developed it at SME/startup and later collaborate with well-developed big medtech companies. Mainly, it was an idea and willingness to help cancer patients to have safer radiotherapy treatments. Our main goal is to do clinical trials to prove that the BrachyDOSE solution is effective in clinical conditions and enter the EU market with a CE marked product.
Q: Which goals have you achieved?
A: We already have partnerships with Lithuanian, Germany and Estonian hospitals to develop the solution. We were funded by EIT Health InnoStars Awards and Horizon 2020 programmes. Also, we had pre-clinical testing results leading us to clinical trial.
Q: How has EuroQuity initiatives helped you in achieving them?
A: EuroQuity helped us to extend our network and visibility of the solution in Central Europe area. We also gained the contacts with Medicen Paris Region, which is our first step in getting to know the French market.
Q: Would you recommend EuroQuity to other companies? If so, Why?
A: We would recommend EuroQuity for SMEs and startups which seeks to expand their business and clinical partners network in EU and get vide visibility among European investors.
Read more success stories in EuroQuiry blog.